J-Alex Trial: Should Alecensa Replace Xalkori As First-Line Alk Therapy

J-Alex Trial: Should Alecensa Replace Xalkori as First-Line ALK Therapy?

GRACE - Global Resource for Advancing Cancer Education

Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC?

GRACE - Global Resource for Advancing Cancer Education

Dr. Shaw on Alectinib as First-Line Therapy in Lung Cancer

A Practice Change for ALK+ Lung Cancer Patients, Alecensa for First Line Treatment

GRACE - Global Resource for Advancing Cancer Education

Phase 3 ALEX Study: Comparing Alecensa to Xalkori in ALK+ Lung Cancer

Cancer Therapy Advisor

Dr. Camidge on the ALEX Trial in Patients With ALK+ NSCLC

ALK-Positive NSCLC: ALEX Trial

ALEX: alectinib is the best first-line therapy available for ALK-positive NSCLC

Key findings of the ALEX study: Improved therapeutic options for ALK-positive NSCLC

Updates in ALK+ lung cancer: GLASS, ALEX, ALTA-1L and CROWN

Management of frontline ALK+ NSCLC: brigatinib vs. alectinib

Alectinib eclipses crizotnib for ALK positive lung cancer

Progression in ALK+ NSCLC After Frontline Therapy

Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLC

Updated Data from Phase 2 Study of Alectinib in ALK–Positive Non–Small–Cell Lung Cancer

Phase III Results for Alectinib Compared With Crizotinib in ALK+ Metastatic NSCLC

Targeted Oncology

Exciting results from the ALEX trial

J-ALEX, ALTA and ALK+/ROS1 Making News in ALK+ NSLC

Dr. Neal Debates Whether Alectinib Will Become the Standard Frontline Thera for ALK+ NSCLC

First and Second Generation ALK Inhibitors for the Treatment of Lung Cancer